SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following positive news of UAE regulatory approval for its immunotherapy drug Anktiva, fueling community discussion about global expansion and the company's long-term commercial potential. Investors remain focused on the upcoming earnings report, debating the company's revenue growth trajectory against concerns over high cash burn and the ongoing short interest.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir Technologies is surging following an exceptional earnings report that featured massive revenue growth and increased full-year guidance, effectively fueling community sentiment and triggering aggressive upgrades from analysts. Investors are actively debating the company's valuation versus its AI-driven momentum, with many bulls calling for significant price appreciation as the stock breaks past previous resistance levels.

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

Cipher Digital is trending as investors aggressively rotate back into AI infrastructure and energy-intensive data center stocks, buoyed by signals of sustained hyperscaler demand for compute capacity. The market is focusing on the company's progress in executing its buildout schedule and securing long-term contracts, which many in the community view as an essential hedge against broader market volatility.

Snap, Inc. is a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Investors are closely monitoring Snap's leadership following anticipated media appearances that have fueled community concerns regarding the company's competitive positioning and strategic execution within the social media sector.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

Applied Optoelectronics is experiencing intense volatility driven by speculation over a potential U.S. government ban on Chinese optical transceivers, which investors see as a major catalyst for domestic suppliers to capture displaced market share. While some community members are betting on a massive breakout, others remain skeptical, warning of the stock's historical tendency for dilution and susceptibility to aggressive algorithmic trading.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is currently navigating a significant digital distribution reset in China, sparking debate among investors about the long-term effectiveness of cutting off third-party retailers to improve brand control. While some in the community see the stock as a deep-value turnaround opportunity, others remain skeptical, pointing to intense competitive pressures and the stock's persistent inability to sustain upward momentum.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is seeing heightened investor attention as community members debate the impact of potential US restrictions on Chinese data center components and the company's strategic positioning within the AI photonics sector. While some participants are wary of volatility and the lack of immediate revenue, others are actively accumulating shares, citing strong institutional backing, significant cash reserves, and optimism regarding upcoming earnings and production partnerships.

Caterpillar, Inc. engages in the business of manufacturing construction and mining equipment, off-highway diesel and natural gas engines, industrial gas turbines, and diesel-electric locomotives. It operates through the following segments: Construction Industries, Resource Industries, Power and Energy, and All Other. The Construction Industries segment is involved in supporting customers using machinery in infrastructure and building construction applications. The Resource Industries segment offers machinery in mining, heavy construction, quarry, and aggregates. The Power and Energy segment focuses on reciprocating engines, turbines, diesel-electric locomotives, and related services across industries serving oil and gas, power generation, industrial, and transportation applications including marine- and rail-related businesses. The All Other segment includes activities such as the business strategy, product management and development, manufacturing, and sourcing of wear and maintenance components products, parts distribution, integrated logistics solutions, distribution services responsible for dealer development, and administration. The company was founded on April 15, 1925, and is headquartered in Irving, TX.

Caterpillar Inc.

Caterpillar is rallying on the back of a record-breaking quarterly earnings beat, with strong revenue growth driven by significant demand for power generation and infrastructure buildouts. Investors are actively debating whether the stock's valuation is becoming overextended due to its newfound status as an AI-infrastructure play or if the sustained backlog and project pipeline justify its current momentum.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is trending as shareholders weigh strong earnings and a raised revenue outlook against ongoing frustration with the stock's stagnant price performance. The community remains divided between investors looking to hold for the attractive dividend yield and those calling for management changes due to persistent range-bound trading.

McDonald's Corp. engages in the operation and franchising of restaurants. The firm operates through the following segments: U.S., International Operated Markets, and International Developmental Licensed Markets and Corporate. The U.S. segment focuses its operations on the United States. The International Operated Markets segment consists of operations and the franchising of restaurants in Australia, Canada, France, Germany, Italy, the Netherlands, Russia, Spain, and the U.K. The International Developmental Licensed Markets and Corporate segment consists of developmental licensee and affiliate markets in the McDonald’s system. Its products include Big Mac, Quarter Pounder with Cheese, Filet-O-Fish, several chicken sandwiches, Chicken McNuggets, wraps, McDonald's Fries, salads, oatmeal, shakes, McFlurry desserts, sundaes, soft serve cones, pies, soft drinks, coffee, and McCafe beverages. The company was founded by Raymond Albert Kroc on April 15, 1955 and is headquartered in Chicago, IL.

McDonald`s Corp

McDonald's Corp

McDonald's is trending following a mixed Q2 earnings report that beat adjusted EPS estimates but fell slightly short on revenue and U.S. same-store sales. Community sentiment is sharply divided between investors viewing the stock as an undervalued dividend-paying defensive play and others expressing skepticism over slowing growth and shifting consumer habits.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$AINMF Just interviewed @NetraMark_AI $AIAI.CN / $AINMF one of the most interesting AI companies in the clinical-trial space. 
 
We covered: 
• Why 60–90% of trials fail 
• How “personas” can save or rescue Phase 2/3 studies 
• Their partnership with Worldwide Clinical Trials 
• FDA meeting coming this December 
• NIMH collaboration + peer-reviewed publication 
 
This company is doing things most AI companies can’t — explainable, regulator-aligned, real-world AI. 
 
Not investment advice. I do not own shares and I was not paid. 
 
Full interview 👇 
🎥 https://youtu.be/Ae2fSzLXUiE?si=97M_4JPbJ1rulwW_

SmallCap Communications

NetraMark AI (CSE: AIAI | OTCQB: AINMF | FRA: PF0) AI is changing how drugs are developed. In this MidDay Bell interview, I sit down with George Achilleos, CEO of NetraMark, and Dr. Luca Pani, Chief Innovation & Regulatory Officer (former Director General of Italy's Medicines Agency; EMA committees).

YouTube

How NetraMark's Explainable AI Could Transform Clinical Trials (CSE: AIAI | OTCQB: AINMF | FRA: PF0)

StockTwits Web

NetraMark Holdings Inc

 one of the most interesting AI companies in the clinical-trial space. 
 
We covered: 
• Why 60–90% of trials fail 
• How “personas” can save or rescue Phase 2/3 studies 
• Their partnership with Worldwide Clinical Trials 
• FDA meeting coming this December 
• NIMH collaboration + peer-reviewed publication 
 
This company is doing things most AI companies can’t — explainable, regulator-aligned, real-world AI. 
 
Not investment advice. I do not own shares and I was not paid. 
 
Full interview 👇 
🎥 